Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

Oncoimmunology · 2026 · PMC13173999 · PMID 42126144

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantp = 0.05actually significant

Pairwise comparisons using Log–rank test showed that there was significant difference in PFS ( Figure 3G ) between groups A and C ( p = 0.008), but marginally significant between groups A and B ( p = 0.05) and groups B and C ( p = 0.068), based on Bonferroni–Holm method of adjustment.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.